drugset
drugset / Trial / NCT01310816

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

NCT01310816 ↗

Phase 2 Completed 105 enrolled Infinity Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

IPI-926 is an inhibitor of the hedgehog pathway. IPI-926 may improve therapeutic outcomes in patients with Chondrosarcoma.

Timeline

Start
2011-02
Primary completion
2013-11
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Patidegib Small molecule — Oral

Indications

chondrosarcoma